ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors, Announces Licensing Deal and Leadership Appointments

ImmunoScape, a Singapore-based biotech firm, has licensed Cue Biopharma's Immuno-STAT molecules for solid tumor cancer treatment. The deal enables a "Seed-and-Boost" approach, combining TCR therapy with Immuno-STAT molecules to expand infused tumor-targeting T-cells and eliminate systemic toxicity. ImmunoScape's clinical program targets high-need cancers such as lung, pancreatic, and ovarian cancer, with IND-enabling studies set to begin by 2027.